      patients develop acute toxicity in the first cohort, the study will be terminated). Patients
      life-threatening toxicity, further accrual is suspended. [APA 5/26/98: An assessment of the
          -  Any indications for acetylsalicylic acid (ASA)|Both|18 Years|65 Years|No|||May 2013|January 26, 2015|April 9, 2002|Yes|Yes|Slow recruitment.|No|January 26, 2015|https://clinicaltrials.gov/show/NCT00033371||204078|Following reports of COX-2 inhibitor-associated cardiovascular toxicities, trial suspended from December 17, 2004 to March 18, 2005 pending reevaluation of cardiovascular risks, only two sites resumed the trial.
      that are less toxic to or can eventually be withdrawn from transplant recipients are needed.
      toxic to or can eventually be withdrawn from transplant recipients are needed. This study
             study physician.|Both|18 Years|N/A|No|||March 2011|March 28, 2011|July 22, 2005|Yes|Yes|The study was terminated due to hepatoxicity of compound|||https://clinicaltrials.gov/show/NCT00123890||197646|
      accrual will be suspended until such time as the cause of the severe treatment toxicity can
          -  Concurrent use of other anti-cancer agents or treatments|Both|18 Years|80 Years|No|||November 2015|November 11, 2015|September 1, 2005|Yes|Yes|Toxicity|No|December 19, 2012|https://clinicaltrials.gov/show/NCT00142168||196265|Due to toxicity, study was terminated.
             study physician.|Both|18 Years|N/A|No|||March 2011|March 28, 2011|September 13, 2005|Yes|Yes|The study was terminated due to hepatoxicity of compound|||https://clinicaltrials.gov/show/NCT00197145||192132|
             study physician.|Both|18 Years|N/A|No|||March 2011|March 28, 2011|September 12, 2005|Yes|Yes|The study was terminated due to hepatoxicity of compound|||https://clinicaltrials.gov/show/NCT00197197||192128|
          7. Patients with Grade 2 or higher neuropathy [NCI Common toxicity criteria].|Female|N/A|N/A|No|||April 2007|April 20, 2007|November 1, 2005|||Regulatory issues(trial temporarily suspended December 28, 2005. Permanently suspended January
      current status. The patient could be withdrawn from the study if the side effect/toxicity
    (21%) of 24 enrolled patients had a CR so the study was terminated.|No|June 3, 2015|https://clinicaltrials.gov/show/NCT00268242||186807|If </= 5 of 1st 18 pts had a CR, study would stop (otherwise, another 22 pts would be accrued). Study would stop if >4 of 1st 10 or 10 of 1st 25 pts had unacceptable toxicity per protocol & Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0
      criterion, including those withdrawn prematurely for reasons other than toxicity, will be
      those withdrawn prematurely for reasons other than toxicity, will be replaced. Enrollment of
          -  Known human immunodeficiency virus (HIV)|Female|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subjects|Yes||https://clinicaltrials.gov/show/NCT00277290||186134|
          -  Known HIV|Both|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subjects|No||https://clinicaltrials.gov/show/NCT00277303||186133|
          -  Known HIV|Both|18 Years|N/A|No|||February 2010|February 18, 2010|March 16, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subjects|No||https://clinicaltrials.gov/show/NCT00304590||184097|
          -  Known HIV|Both|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subejcts|No||https://clinicaltrials.gov/show/NCT00277329||186131|
          -  Known HIV|Both|18 Years|N/A|No|||February 2010|February 18, 2010|May 4, 2006|Yes|Yes|Study was terminated due to cardiac toxicities|No||https://clinicaltrials.gov/show/NCT00322673||182728|
             formulated in Cremophor EL^Â®, other platinol compounds, or mannitol|Female|18 Years|N/A|No|||November 2012|November 6, 2012|May 30, 2006|Yes|Yes|Study was terminated due to lack of available funding.|No|November 23, 2009|https://clinicaltrials.gov/show/NCT00331422||182075|1 of the 2 evaluable patients was switched from Paclitaxel to Taxotere during the course of her treatment due to toxicity (adverse effects), but since it remains a platinum-based chemotherapy she is included in the evaluable group.
      Note: Study was previously suspended due to non-clinical reports of hepatotoxicity and
      terminated early with no dose chosen if the lowest dose is excessively toxic.
             receiving combination antiretroviral therapy when indicated|Both|18 Years|N/A|No|||October 2013|May 12, 2014|December 27, 2006|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00416793||175687|Given the toxicity and lack of objective responses observed with this regimen, the protocol met prospective criteria for early stopping and was terminated.
      evidence of biochemical and/or clinical drug toxicity will be withdrawn from the study and
          -  Hematological toxicities from previous chemotherapies terminated or <= 2
             immunotherapy, or biologic therapy)|Both|1 Year|21 Years|No|||August 2014|August 7, 2014|April 9, 2007|No|Yes|Study withdrawn because of toxicity reported on the adult phase 1 trial.|||https://clinicaltrials.gov/show/NCT00458744||172516|
          8. Participation in other trial with investigational drug or treatment modality.|Both|N/A|N/A|No|||January 2011|April 4, 2011|September 17, 2007||No|Study terminated due to toxicity|No||https://clinicaltrials.gov/show/NCT00531076||167064|
             hypothyroidism who are stable on thyroid replacement are eligible.|Both|18 Years|N/A|No|||August 2013|August 15, 2013|October 26, 2007|No|Yes|Study terminated due to LBH589 toxicity.|No||https://clinicaltrials.gov/show/NCT00550199||165623|
             finished the treatment or suspended it due to disease progression, toxicity or other
          -  Patients with known hypersensitivity to paclitaxel and/or carboplatin are ineligible.|Female|19 Years|N/A|No|||January 2012|February 28, 2012|December 21, 2007|Yes|Yes|low accrual|No|September 21, 2011|https://clinicaltrials.gov/show/NCT00584909||163022|This study was terminated early due to slow accrual. 4 patients withdrew from the study due to side-effects from the treatment. All 9 patients were evaluable for toxicity and PFS.
          -  No concurrent Hypericum perforatum (St. Johns wort)|Both|18 Years|N/A|No|||September 2015|September 18, 2015|October 13, 2007|Yes|Yes|Toxicity|No|August 19, 2015|https://clinicaltrials.gov/show/NCT00544908||166017|Study was terminated early due to toxicity.
          -  Other exclusion criteria may apply|Female|18 Years|48 Years|No|||August 2014|August 8, 2014|November 7, 2007|Yes|Yes|Clinical hold for safety|No|June 24, 2014|https://clinicaltrials.gov/show/NCT00556075||165180|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with complete study data.
      progression, toxicity, withdrawn consent or going onto non-protocol therapy.
             peripheral neurotoxicity.|Male|18 Years|N/A|No|||January 2012|January 20, 2012|March 12, 2008|Yes|Yes|According to the protocol, the sponsor terminated the study after it was determined that less
             heart valves or chronic atrial fibrillation.|Both|18 Years|N/A|No|||August 2014|August 8, 2014|April 24, 2008|Yes|Yes|lack of response activity in the setting of an unacceptable toxicity profile|No|April 11, 2014|https://clinicaltrials.gov/show/NCT00667277||156805|The study was terminated due to lack of response activity in the setting of an unacceptable toxicity profile at the completion of the first stage.
          -  Known active infection with HIV; Hepatitis A, B or C; gonorrhea; or chlamydia|Female|18 Years|45 Years|No|||August 2014|August 5, 2014|May 22, 2008|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00683917||155542|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
          -  Symptomatic angina or uncontrolled congestive heart failure|Both|18 Years|80 Years|No|||September 2014|September 24, 2014|March 24, 2008|Yes|Yes|Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.|No|February 12, 2014|https://clinicaltrials.gov/show/NCT00642746||158680|Study terminated before target enrollment was reached due to excessive toxicities and limited enrollment.
                  to the start of the study|Female|18 Years|45 Years|No|||August 2014|August 5, 2014|June 18, 2008|Yes|Yes|Repros stopped study for safety and FDA put study on hold because of safety.|No|June 23, 2014|https://clinicaltrials.gov/show/NCT00702702||154116|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
      volunteers|Study was suspended due to inconclusive toxicology findings regarding the used patch
          -  Concurrent anti-coagulation treatment, such as warfarin or heparin, allowed|Both|18 Years|N/A|No|||November 2014|November 5, 2014|July 31, 2008|Yes|Yes|Extreme toxicity|No|July 8, 2014|https://clinicaltrials.gov/show/NCT00726986||152278|This study was terminated after enrolling 18 patients on the basis of excessive toxicity observed and preliminary efficacy data showing that study was unlikely to meet primary end point.
             antibodies.|Female|18 Years|48 Years|No|||August 2014|August 5, 2014|August 13, 2008|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00735553||151624|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
        Additional exclusion criteria may apply.|Female|18 Years|48 Years|No|||August 2014|August 5, 2014|August 14, 2008|Yes|Yes|Repros stopped study for safety and FDA put study on hold.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00737282||151493|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
                  to the start of the study|Female|18 Years|48 Years|No|||August 2014|August 5, 2014|November 3, 2008|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00785356||147844|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
      results in toxicity leading to a delay in surgery, the study will be terminated.
          -  Additional exclusion criteria may apply|Female|18 Years|48 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|November 6, 2008|Yes|Yes|Increased LFTs|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00787618||147674|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
          -  intoxication or drug overdose|Both|18 Years|N/A|No|||February 2010|April 1, 2010|February 13, 2009|Yes|Yes|Study has been withdrawn as the H1N1 epidemic made this study redundant|No||https://clinicaltrials.gov/show/NCT00844155||143389|
             3[CTCAE v3.0] as grade 2 or greater neurosensory or neuromotor toxicity|Both|18 Years|70 Years|No|||March 2013|March 7, 2013|January 27, 2009|Yes|Yes|terminated for lack of enrollment|No|February 25, 2013|https://clinicaltrials.gov/show/NCT00832299||144287|
          -  Subjects with a Body Mass Index (BMI) below 18 or over 39|Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|April 14, 2009|Yes|Yes|Repros stopped study for safety and the FDA put the study on hold for safety.|No|June 26, 2014|https://clinicaltrials.gov/show/NCT00881608||140552|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
             antibodies.|Female|18 Years|48 Years|No|||August 2014|August 5, 2014|February 27, 2009|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00853567||142676|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
          -  Previous medical history of etilism or/and pancreatic disease|Both|18 Years|75 Years|No|||July 2015|July 7, 2015|May 15, 2009||No|The study was terminated due to excessive toxicity and low compliance to the protocol scheme.|No||https://clinicaltrials.gov/show/NCT00905398||138781|
      toxicity, at which time the subjects will be withdrawn from the treatment phase. If a
          -  All other subjects|Female|18 Years|50 Years|No|||August 2014|August 8, 2014|August 11, 2009|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00958893||134719|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
          -  Pregnant or nursing females; females of childbearing potential.|Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|July 13, 2009|No|Yes|This study was terminated on January 6, 2010, due to toxicology findings in animals exposed to
             them at an unacceptably high risk for toxicities.|Both|18 Years|N/A|No|||September 2011|December 22, 2014|December 17, 2009|No|Yes|This study has been terminated.|No||https://clinicaltrials.gov/show/NCT01035216||128922|
             participating in ZPU-301, ZPU-302, ZPU-303, or ZPU-304|Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 5, 2014|February 10, 2010|Yes|Yes|Repros stopped study due to safety and FDA placed study on hold|No|June 25, 2014|https://clinicaltrials.gov/show/NCT01069120||126386|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
      for toxicity. Patients will be withdrawn from the study if they develop progressive disease,
          -  Thyrotoxicosis|Female|18 Years|65 Years|No|||July 2015|July 20, 2015|April 16, 2010|Yes|Yes|Resources not available to complete.|No|June 18, 2015|https://clinicaltrials.gov/show/NCT01106846||123505|Study was terminated early.
      01910.Na for reasons unrelated to toxicity, or if the patient is withdrawn due to a DLT.
      terminated secondary to toxicity or progression of OPG, or 2) developed recurrence of OPG
      treatment with carboplatin or cisplatin, which was terminated secondary to toxicity or
      prior treatment with carboplatin or cisplatin, which was terminated secondary to toxicity or
             treatment with carboplatin or cisplatin, which was terminated secondary to toxicity
      that the trial be terminated after an initial stage if the number of observed toxicities
        and TJU BMT Program SOP CP: P009.03.|Both|18 Years|N/A|No|||October 2014|October 21, 2014|May 4, 2011|Yes|Yes|Poor accrual|No|October 21, 2014|https://clinicaltrials.gov/show/NCT01350258||104930|Study was terminated due to extreme toxicity. The study was closed before any data could be collected.
                  toxicity is permitted if terminated at least 5 halflives prior to Day 1 of trial
          -  Prior therapy with immune stimulating agents|Both|18 Years|N/A|No|||December 2014|December 10, 2014|July 21, 2011|Yes|Yes|More than 2 of 6 patients treated experienced dose limiting toxicities.|No|April 21, 2014|https://clinicaltrials.gov/show/NCT01400451||101097|In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.
          -  Patients with active infections that meet grade 3-4 toxicity criteria.|Both|2 Years|N/A|No|||December 2014|December 23, 2014|June 13, 2011|Yes|Yes|Study has been suspended after the event of an serious adverse event.|||https://clinicaltrials.gov/show/NCT01377532||102850|
             completing the prior study (due to disease progression, toxicity, withdrawn consent,
             are known inhibitors or inducers of CYP3A4|Female|18 Years|N/A|No|||July 2014|July 18, 2014|August 18, 2011|Yes|Yes|See termination reason in detailed description.|No|July 18, 2014|https://clinicaltrials.gov/show/NCT01430585||98793|Study was prematurely terminated due to PF-04691502 tolerability findings that prompted Sponsor to re-evaluate strategic goals of program. Unexpected frequency of severe skin toxicity was observed and no participant was enrolled in phase 2 of study.
      toxicity will be withdrawn from treatment. In the Follow-Up Phase, patients whose disease
               -  Subjects who have withdrawn from standard treatment due to unacceptable toxicity
      experiences a dose limiting toxicity, the study will be terminated. Patients who demonstrate
      chemoradiation therapy for rectal cancer was terminated due to toxicity, including
      toxicity or withdrawn of patients occured) After 3 and 6 cycles, an evaluation will be done
          -  Subject is mentally or legally incapacitated|Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|November 1, 2012||No|Study was terminated due to toxicology findings after screening started but before first
      toxicity has occurred), the study is terminated by the sponsor, the participant withdraws
      the study (2 per arm) after which accrual will be suspended to review the toxicity
      of accrued patients experience DLT, then accrual will be suspended and reported toxicity
      systemic and ocular toxicities and adverse events. The number of participants withdrawn from
      systemic and ocular toxicities and adverse events. The number of participants withdrawn from
             disease progression, toxicity, withdrawn consent, other).
      patients unless undue toxicity is encountered or the accrual is terminated at the interim
      toxicity S-1 dose will be adjusted or study treatment will be terminated.
      unacceptable toxicity or if the patient requests to be withdrawn from the study. If one of
      unacceptable toxicity or if the patient requests to be withdrawn from the study.
      described. In patients with grade 3-4 toxicity, RT was suspended and treatment was resumed
          -  Unresolved Grade 2 or greater toxicity in Study C-935788-050|Both|18 Years|72 Years|No|||October 2015|October 21, 2015|April 29, 2015|Yes|Yes|Study withdrawn prior to enrollment of first subject|No||https://clinicaltrials.gov/show/NCT02433236||22050|
         12. Patients with thyroid dysfunction not responsive to therapy.|Both|18 Years|N/A|No|||November 2015|November 13, 2015|November 12, 2015||No|Study terminated following Phase I NCT00791271, no progression to Phase II due to toxicity and
          -  Patients who were withdrawn from first line treatment due to toxicity without
      grade 3 magnesium valproate will be suspended for 3 days or until the toxicity is at least
      suspended for 3 days or until the toxicity is at least grade 2 and will restart to 50% of
      terminated if >30% acute grade 2 or >5% grade 3 or greater toxicity is observed as a result
             suspended due to toxicity or other reasons.
      toxicities are observed in any one of the treatment arms, the study will be terminated
